Browse > Article
http://dx.doi.org/10.5483/BMBRep.2019.52.7.152

Highlighted STAT3 as a potential drug target for cancer therapy  

Lee, Haeri (Department of Pharmacology and Biomedical Sciences, Seoul National University College of Medicine)
Jeong, Ae Jin (Department of Pharmacology and Biomedical Sciences, Seoul National University College of Medicine)
Ye, Sang-Kyu (Department of Pharmacology and Biomedical Sciences, Seoul National University College of Medicine)
Publication Information
BMB Reports / v.52, no.7, 2019 , pp. 415-423 More about this Journal
Abstract
Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that regulates cell proliferation, differentiation, apoptosis, angiogenesis, inflammation and immune responses. Aberrant STAT3 activation triggers tumor progression through oncogenic gene expression in numerous human cancers, leading to promote tumor malignancy. On the contrary, STAT3 activation in immune cells cause elevation of immunosuppressive factors. Accumulating evidence suggests that the tumor microenvironment closely interacts with the STAT3 signaling pathway. So, targeting STAT3 may improve tumor progression, and anti-cancer immune response. In this review, we summarized the role of STAT3 in cancer and the tumor microenvironment, and present inhibitors of STAT3 signaling cascades.
Keywords
Cancer stem cells; Cancer therapy; Immune suppression; STAT3; Tumor microenvironment;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Jinxia D, Fedora G and Nouri N (2007) Small Molecule Inhibitors of Stat3 Signaling Pathway. Curr Cancer Drug Targets 7, 91-107   DOI
2 Epling-Burnette PK, Liu JH, Catlett-Falcone R et al (2001) Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107, 351-362   DOI
3 Chen H, Yang Z, Ding C et al (2013) Discovery of O-Alkylamino-Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents. ACS Med Chem Lett 4, 180-185   DOI
4 Kanai M, Konda Y, Nakajima T et al (2003) Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway. Oncogene 22, 548-554   DOI
5 Turkson J, Ryan D, Kim JS et al (2001) Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation. J Biol Chem 276, 45443-45455   DOI
6 Siddiquee KAZ, Gunning PT, Glenn M et al (2007) An Oxazole-Based Small-Molecule Stat3 Inhibitor Modulates Stat3 Stability and Processing and Induces Antitumor Cell Effects. ACS Chem Biol 2, 787-798   DOI
7 Zhang X, Sun Y, Pireddu R et al (2013) A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation. Cancer Res 73, 1922-1933   DOI
8 Kumar A and Bora U (2012) Molecular docking studies on inhibition of Stat3 dimerization by curcumin natural derivatives and its conjugates with amino acids. Bioinformation 8, 988-993   DOI
9 Shin D-S, Kim H-N, Shin KD et al (2009) Cryptotanshinone Inhibits Constitutive Signal Transducer and Activator of Transcription 3 Function through Blocking the Dimerization in DU145 Prostate Cancer Cells. Cancer Res 69, 193-202   DOI
10 Song H, Wang R, Wang S and Lin J (2005) A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A 102, 4700-4705   DOI
11 Schust J, Sperl B, Hollis A, Mayer TU and Berg T (2006) Stattic: A Small-Molecule Inhibitor of STAT3 Activation and Dimerization. Chem Biol 13, 1235-1242   DOI
12 Fletcher S, Page BDG, Zhang X et al (2011) Antagonism of the Stat3-Stat3 Protein Dimer with Salicylic Acid Based Small Molecules. Chem Med Chem 6, 1459-1470   DOI
13 Xu Q, Briggs J, Park S et al (2005) Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24, 5552-5560   DOI
14 Pancotti F, Roncuzzi L, Maggiolini M and Gasperi-Campani A (2012) Caveolin-1 silencing arrests the proliferation of metastatic lung cancer cells through the inhibition of STAT3 signaling. Cell Signal 24, 1390-1397   DOI
15 Wei D, Le X, Zheng L et al (2003) Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22, 319-329   DOI
16 Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H and Yu H (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118, 3367-3377   DOI
17 Jung JE, Lee HG, Cho IH et al (2005) STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J 19, 1296-1298   DOI
18 Cheng GZ, Zhang W, Sun M et al (2008) Twist Is Transcriptionally Induced by Activation of STAT3 and Mediates STAT3 Oncogenic Function. J Biol Chem 283, 14665-14673   DOI
19 Lin Y-M, Wang C-M, Jeng J-C, Leprince D and Shih H-M (2013) HIC1 interacts with and modulates the activity of STAT3. Cell Cycle 12, 2266-2276   DOI
20 Wojcik EJ, Sharifpoor S, Miller NA et al (2006) A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells. Oncogene 25, 2773-2784   DOI
21 Banerjee K and Resat H (2016) Constitutive activation of STAT3 in breast cancer cells: A review. Int J Cancer 138, 2570-2578   DOI
22 Wendt MK, Balanis N, Carlin CR and Schiemann WP (2014) STAT3 and epithelial-mesenchymal transitions in carcinomas. JAK-STAT 3, e28975-e28975   DOI
23 Chen M, Liu Y, Varley P et al (2015) High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21-Mediated Matrix Metalloproteinase Activity. Cancer Res 75, 1645-1656   DOI
24 Ge H, Liu H, Fu Z and Sun Z (2012) Therapeutic and Preventive Effects of an Epidermal Growth Factor Receptor Inhibitor on Oral Squamous Cell Carcinoma. J Int Med Res 40, 455-466   DOI
25 Turkson J, Zhang S, Palmer J et al (2004) Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 3, 1533-1542
26 Nagel-Wolfrum K, Buerger C, Wittig I, Butz K, Hoppe-Seyler F and Groner B (2004) The Interaction of Specific Peptide Aptamers With the DNA Binding Domain and the Dimerization Domain of the Transcription Factor Stat3 Inhibits Transactivation and Induces Apoptosis in Tumor Cells. Mol Cancer Res 2, 170-182
27 Buerger C, Nagel-Wolfrum K, Kunz C et al (2003) Sequence-specific Peptide Aptamers, Interacting with the Intracellular Domain of the Epidermal Growth Factor Receptor, Interfere with Stat3 Activation and Inhibit the Growth of Tumor Cells. J Biol Chem 278, 37610-37621   DOI
28 Huang C, Cao J, Huang KJ et al (2006) Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro. Cancer Sci 97, 1417-1423   DOI
29 Ferrajoli A, Faderl S, Van Q et al (2007) WP1066 Disrupts Janus Kinase-2 and Induces Caspase-Dependent Apoptosis in Acute Myelogenous Leukemia Cells. Cancer Res 67, 11291-11299   DOI
30 Pardanani A, Hood J, Lasho T et al (2007) TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21, 1658   DOI
31 Scuto A, Krejci P, Popplewell L et al (2010) The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 25, 538   DOI
32 Oyaizu T, Fung SY, Shiozaki A et al (2012) Src tyrosine kinase inhibition prevents pulmonary ischemia-reperfusioninduced acute lung injury. Intensive Care Med 38, 894-905   DOI
33 Yan S, Li Z and Thiele CJ (2013) Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo. Oncotarget 4, 433-445   DOI
34 Chen Z, Lee FY, Bhalla KN and Wu J (2006) Potent Inhibition of Platelet-Derived Growth Factor-Induced Responses in Vascular Smooth Muscle Cells by BMS-354825 (Dasatinib). Mol Pharmacol 69, 1527-1533   DOI
35 Michels S, Trautmann M, Sievers E et al (2013) SRC Signaling Is Crucial in the Growth of Synovial Sarcoma Cells. Cancer Res 73, 2518-2528   DOI
36 Chang AY and Wang M (2013) Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells. BMC Cancer 13, 267   DOI
37 Premkumar D, Jane E, Agostino N, Scialabba J and Pollack I (2010) Dasatinib synergizes with JSI-124 to inhibit growth and migration and induce apoptosis of malignant human glioma cells. J Carcinog 9, 7   DOI
38 Antonarakis ES, Heath EI, Posadas EM et al (2013) A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology 71, 883-892   DOI
39 Gangadhar TC, Clark JI, Karrison T and Gajewski TF (2013) Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs 31, 769-773   DOI
40 Seltana A, Guezguez A, Lepage M, Basora N and Beaulieu JF (2013) Src family kinase inhibitor PP2 accelerates differentiation in human intestinal epithelial cells. Biochem Biophys Res Commun 430, 1195-1200   DOI
41 Buchert M, Burns CJ and Ernst M (2015) Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene 35, 939   DOI
42 Hanahan D and Weinberg Robert A (2011) Hallmarks of Cancer: The Next Generation. Cell 144, 646-674   DOI
43 Yu H and Jove R (2004) The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 4, 97-105   DOI
44 Xiong H, Hong J, Du W et al (2012) Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J Biol Chem 287, 5819-5832   DOI
45 Kalluri R (2003) Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3, 422-433   DOI
46 Dechow TN, Pedranzini L, Leitch A et al (2004) Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A 101, 10602-10607   DOI
47 Kim BH, Won C, Lee YH et al (2013) Sophoraflavanone G induces apoptosis of human cancer cells by targeting upstream signals of STATs. Biochem Pharmacol 86, 950-959   DOI
48 Aittomaki S and Pesu M (2014) Therapeutic Targeting of the JAK/STAT Pathway. Basic Clin Pharmacol Toxicol 114, 18-23   DOI
49 Plimack ER, Lorusso PM, McCoon P et al (2013) AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. Oncologist 18, 819-820   DOI
50 Furtek SL, Backos DS, Matheson CJ and Reigan P (2016) Strategies and Approaches of Targeting STAT3 for Cancer Treatment. ACS Chem Biol 11, 308-318   DOI
51 Puls LN, Eadens M and Messersmith W (2011) Current status of SRC inhibitors in solid tumor malignancies. Oncologist 16, 566-578   DOI
52 Nam S, Wen W, Schroeder A et al (2013) Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells. Mol Oncol 7, 369-378   DOI
53 Liu L, Gaboriaud N, Vougogianopoulou K et al (2014) MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells. Cancer Biol Ther 15, 178-184   DOI
54 Herbeuval J-P, Lelievre E, Lambert C, Dy M and Genin C (2004) Recruitment of STAT3 for Production of IL-10 by Colon Carcinoma Cells Induced by Macrophage-Derived IL-6. J Immunol 172, 4630-4636   DOI
55 Itoh M, Murata T, Suzuki T et al (2006) Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 25, 1195-1204   DOI
56 Sano S, Itami S, Takeda K et al (1999) Keratinocytespecific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 18, 4657-4668   DOI
57 Silver DL, Naora H, Liu J, Cheng W and Montell DJ (2004) Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 64, 3550-3558   DOI
58 Stumhofer JS, Silver JS, Laurence A et al (2007) Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 8, 1363   DOI
59 Saudemont A, Jouy N, Hetuin D and Quesnel B (2005) NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood 105, 2428-2435   DOI
60 Chen J, Wang J, Lin L et al (2012) Inhibition of STAT3 Signaling Pathway by Nitidine Chloride Suppressed the Angiogenesis and Growth of Human Gastric Cancer. Mol Cancer Ther 11, 277-287   DOI
61 Wang T, Niu G, Kortylewski M et al (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10, 48-54   DOI
62 Herrmann A, Kortylewski M, Kujawski M et al (2010) Targeting Stat3 in the Myeloid Compartment Drastically Improves the in vivo Antitumor Functions of Adoptively Transferred T Cells. Cancer Res 70, 7455-7464   DOI
63 Thakur R, Trivedi R, Rastogi N, Singh M and Mishra DP (2015) Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci Rep 5, 10194   DOI
64 Blaylock R (2015) Cancer microenvironment, inflammation and cancer stem cells: A hypothesis for a paradigm change and new targets in cancer control. Surg Neurol Int 6, 92   DOI
65 Huynh J, Chand A, Gough D and Ernst M (2019) Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map. Nat Rev Cancer 19, 82-96   DOI
66 Joyce JA and Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74-80   DOI
67 Spill F, Reynolds DS, Kamm RD and Zaman MH (2016) Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotechnol 40, 41-48   DOI
68 Kortylewski M and Yu H (2008) Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol 20, 228-233   DOI
69 Frank DA (2007) STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 251, 199-210   DOI
70 Roeser JC, Leach SD and McAllister F (2015) Emerging strategies for cancer immunoprevention. Oncogene 34, 6029   DOI
71 Sonnenblick A, Shriki A, Galun E et al (2012) Tissue microarray-based study of patients with lymph nodepositive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis. Clin Transl Oncol 14, 232-236   DOI
72 Zhang X, Hu F, Li G et al (2018) Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling. Cell Death Dis 9, 25   DOI
73 Liu X, He Z, Li C-H, Huang G, Ding C and Liu H (2012) Correlation analysis of JAK-STAT pathway components on prognosis of patients with prostate cancer. Pathol Oncol Res 18, 17-23   DOI
74 Wei W, Tweardy DJ, Zhang M et al (2014) STAT3 Signaling Is Activated Preferentially in Tumor-Initiating Cells in Claudin-Low Models of Human Breast Cancer. Stem Cells 32, 2571-2582   DOI
75 Won C, Kim B-H, Yi EH et al (2015) Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. Hepatology 62, 1160-1173   DOI
76 Haftchenary S, Luchman HA, Jouk AO et al (2013) Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma. ACS Med Chem Lett 4, 1102-1107   DOI
77 Qu Y, Oyan AM, Liu R et al (2013) Generation of Prostate Tumor-Initiating Cells Is Associated with Elevation of Reactive Oxygen Species and IL-6/STAT3 Signaling. Cancer Res 73, 7090-7100   DOI
78 Hossain A, Gumin J, Gao F et al (2015) Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells 33, 2400-2415   DOI
79 Schaefer LK, Ren Z, Fuller GN and Schaefer TS (2002) Constitutive activation of $Stat3{\alpha}$ in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene 21, 2058-2065   DOI
80 van der Zee M, Sacchetti A, Cansoy M et al (2015) IL6/JAK1/STAT3 Signaling Blockade in Endometrial Cancer Affects the $ALDH^{hi}/CD126^{+}$ Stem-like Component and Reduces Tumor Burden. Cancer Res 75, 3608-3622   DOI
81 Geiger JL, Grandis JR and Bauman JE (2016) The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncology 56, 84-92   DOI
82 Li S, Priceman SJ, Xin H et al (2013) Icaritin Inhibits JAK/STAT3 Signaling and Growth of Renal Cell Carcinoma. PLoS One 8, e81657   DOI
83 He G and Karin M (2010) NF-${\kappa}B$ and STAT3 - key players in liver inflammation and cancer. Cell Res 21, 159   DOI
84 Saini U, Naidu S, ElNaggar AC et al (2016) Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene 36, 168   DOI
85 Bar-Natan M, Nelson EA, Xiang M and Frank DA (2012) STAT signaling in the pathogenesis and treatment of myeloid malignancies. JAK-STAT 1, 55-64   DOI
86 Fukuda A, Wang Sam C, Morris John P et al (2011) Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression. Cancer Cell 19, 441-455   DOI
87 Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB and Tweardy DJ (2011) Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 117, 5701-5709   DOI
88 Zhao D, Pan C, Sun J et al (2014) VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene 34, 3107   DOI
89 Gibbs CP, Kukekov VG, Reith JD et al (2005) Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia (New York, N.Y.) 7, 967-976   DOI
90 Marotta LLC, Almendro V, Marusyk A et al (2011) The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors. J Clin Invest 121, 2723-2735   DOI
91 Tseng L-M, Huang P-I, Chen Y-R et al (2012) Targeting Signal Transducer and Activator of Transcription 3 Pathway by Cucurbitacin I Diminishes Self-Renewing and Radiochemoresistant Abilities in Thyroid Cancer-Derived $CD133^+$ Cells. J Pharmacol Exp Ther 341, 410-423   DOI
92 Groner B, Lucks P and Borghouts C (2008) The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol 19, 341-350   DOI
93 Jung JE, Kim HS, Lee CS et al (2008) STAT3 inhibits the degradation of HIF-$1{\alpha}$ by pVHL-mediated ubiquitination. Exp Mol Med 40, 479   DOI
94 Samavati L, Rastogi R, Du W, Huttemann M, Fite A and Franchi L (2009) STAT3 tyrosine phosphorylation is critical for interleukin 1 beta and interleukin-6 production in response to lipopolysaccharide and live bacteria. Mol Immunol 46, 1867-1877   DOI
95 Lin L, Liu A, Peng Z et al (2011) STAT3 Is Necessary for Proliferation and Survival in Colon Cancer-Initiating Cells. Cancer Res 71, 7226-7237   DOI
96 Alas S and Bonavida B (2003) Inhibition of Constitutive STAT3 Activity Sensitizes Resistant Non-Hodgkin's Lymphoma and Multiple Myeloma to Chemotherapeutic Drug-mediated Apoptosis. Clin Cancer Res 9, 316-326
97 Yu H, Pardoll D and Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9, 798   DOI
98 Bromberg J and Darnell JE (2000) The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19, 2468-2473   DOI
99 Kim BH, Yi EH and Ye SK (2016) Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment. Arch Pharm Res 39, 1085-1099   DOI
100 Horiguchi A, Oya M, Marumo K and Murai M (2002) STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. Kidney Int 61, 926-938   DOI
101 Corvinus FM, Orth C, Moriggl R et al (2005) Persistent STAT3 Activation in Colon Cancer Is Associated with Enhanced Cell Proliferation and Tumor Growth. Neoplasia 7, 545-555   DOI
102 Catlett-Falcone R, Landowski TH, Oshiro MM et al (1999) Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells. Immunity 10, 105-115   DOI
103 Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H and Yu H (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118, 3367-3377   DOI
104 Gao H, Priebe W, Glod J and Banerjee D (2009) Activation of Signal Transducers and Activators of Transcription 3 and Focal Adhesion Kinase by Stromal Cell-Derived Factor 1 Is Required for Migration of Human Mesenchymal Stem Cells in Response to Tumor Cell-Conditioned Medium. Stem Cells 27, 857-865   DOI
105 Fujiwara Y, Takeya M and Komohara Y (2014) A novel strategy for inducing the antitumor effects of triterpenoid compounds: blocking the protumoral functions of tumor-associated macrophages via STAT3 inhibition. Biomed Res Int 2014, 348539   DOI
106 Kim KJ, Kwon SH, Yun JH et al (2017) STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression. Oncogene 36, 5445   DOI
107 Wu L, Du H, Li Y, Qu P and Yan C (2011) Signal transducer and activator of transcription 3 (Stat3C) promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis. Am J Pathol 179, 2131-2141   DOI
108 Sun X, Sui Q, Zhang C, Tian Z and Zhang J (2013) Targeting Blockage of STAT3 in Hepatocellular Carcinoma Cells Augments NK Cell Functions via Reverse Hepatocellular Carcinoma-Induced Immune Suppression. Mol Cancer Ther 12, 2885-2896   DOI
109 Haura EB, Turkson J and Jove R (2005) Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2, 315-324   DOI
110 Debnath B, Xu S and Neamati N (2012) Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3) Protein. J Med Chem 55, 6645-6668   DOI